Highlights • Bevacizumab (Avastin®), a VEGF-A targeting monoclonal antibody, was the first approved angiogenesis inhibitor. • Approved in a range of solid tumor indications, bevacizumab is an important part of the standard of care in oncology. • The recently identified immune modulatory roles of VEGF provide a powerful rationale for combination therapies. • First clinical studies of the combination of bevacizumab with immune checkpoint inhibitors have shown efficacy.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Herbert
Contact Herbert, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack